Fulvestrant and Red cell distribution width increased - a phase IV clinical study of FDA data

Summary:

Red cell distribution width increased is reported as a side effect among people who take Fulvestrant (fulvestrant), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Kisqali, and have Breast cancer.

The phase IV clinical study analyzes which people have Red cell distribution width increased when taking Fulvestrant. It is created by eHealthMe based on reports of 15,757 people who have side effects when taking Fulvestrant from the FDA, and is updated regularly.

What is Fulvestrant?

Fulvestrant has active ingredients of fulvestrant. eHealthMe is studying from 15,769 Fulvestrant users. Check the latest studies of Fulvestrant.

What is Red cell distribution width increased?

Red cell distribution width increased is found to be associated with 605 drugs and 656 conditions by eHealthMe. Check the latest studies of Red cell distribution width increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

15,757 people reported to have side effects when taking Fulvestrant.
Among them, 80 people (0.51%) have Red cell distribution width increased.

Could Fulvestrant cause Red cell distribution width increased?

Among these 80 people:

How long have people been on Fulvestrant when they have Red cell distribution width increased? *

What is the gender of people who have Red cell distribution width increased when taking Fulvestrant? *

female: 100 %
male: 0.0 %

What is the age of people who have Red cell distribution width increased when taking Fulvestrant? *

What are other drugs people take besides Fulvestrant? *

What are other side effects people have besides Red cell distribution width increased? *

Red Blood Cell Count Decreased: 69 people, 86.25%
White Blood Cell Count Decreased: 67 people, 83.75%
Haematocrit Decreased: 64 people, 80.00%
Haemoglobin Decreased: 59 people, 73.75%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 44 people, 55.00%
Lymphocyte Count Decreased: 42 people, 52.50%
Mean Cell Haemoglobin Increased (more than normal haemoglobin per red blood cell in a sample of blood): 33 people, 41.25%
Fatigue (feeling of tiredness): 33 people, 41.25%
Mean Cell Volume Increased (more than normal average red blood cell volume): 30 people, 37.50%
Anisocytosis (patient's red blood cells are of unequal size): 28 people, 35.00%

What are the existing conditions these people have? *

Breast Cancer: 36 people, 45.00%
Breast Cancer Metastatic: 35 people, 43.75%
Neuralgia (pain in one or more nerves): 5 people, 6.25%
Bone Disorder: 5 people, 6.25%
Stress And Anxiety: 4 people, 5.00%
Pain: 4 people, 5.00%
Breast Cancer Female: 4 people, 5.00%
Arrhythmias (irregular heartbeat): 4 people, 5.00%
Neoplasm Malignant (cancer tumour): 2 people, 2.50%
Chest Injury: 2 people, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Fulvestrant and have Red cell distribution width increased?

- Check whether Red cell distribution width increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fulvestrant:

Fulvestrant (15,769 reports)

Browse all side effects of Fulvestrant:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red cell distribution width increased:

Red cell distribution width increased (605 drugs)

Browse all the conditions that are associated with Red cell distribution width increased:

Red cell distribution width increased (656 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fulvestrant (the active ingredients of Fulvestrant) and Fulvestrant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.